Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis.

[10] Deucravacitinib was approved for medical use in the United States in September 2022,[7][11][12] and in Australia in December 2022.

[1] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

[7] It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).

[15] The chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms are replaced by deuterium.